Answers are grounded in this paper and cite their sources.
Background Meta‐iodobenzylguanidine radiolabeled with iodine‐131 ( 131 I‐MIBG) is used to treat high‐risk neuroblastoma (HRNBL). Late toxicities of 131 I‐MIBG have not been well studied due to limited survival of patients receiving this therapy for relapsed disease. Methods The Children's Oncology Group LEAHRN study evaluated HRNBL survivors diagnosed after 2000 and alive at least 5 years from diagnosis. Clinical history and the prevalence of late effects were summarized for participants treated with 131 I‐MIBG (cases). Participants who did not receive 131 I‐MIBG were randomly selected and matched by age at diagnosis and relapse history (controls) in a 1:2 case–control study design. Chi‐squared analysis was used to evaluate the association between 131 I‐MIBG and late toxicities. Results Of 375 participants in the LEAHRN analytic cohort, 32 (8.5%) received 131 I‐MIBG. Differences in the proportion with thyroid toxicity and growth failure were observed but not statistically significant. The proportions of other major organ toxicities were not different between cases and controls, including subsequent malignancy. Discussion No statistically significant differences were identified in the burden of late toxicities for HRNBL survivors treated with and without 131 I‐MIBG. A small sample size likely limited the ability to detect statistically significant differences. Our data provide information for follow‐up care of 131 I‐MIBG‐treated survivors and clinical trial design.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: